NASDAQ:RGC
Regencell Bioscience Holdings Limited Stock News
$3.36
-0.160 (-4.55%)
At Close: Jun 28, 2024
HONG KONG–(BUSINESS WIRE)–Regencell Bioscience Holdings Limited (Nasdaq: RGC) (“Regencell”) today announced its interim results from its second efficacy trial. Regencell conducted its second e
HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (Nasdaq: RGC) (“Regencell”) today announced its interim results from its second efficacy trial. Regencell conducted its second eff
HONG KONG--(BUSINESS WIRE)---- $RGC #ADHD--Regencell Bioscience Holdings Limited (Nasdaq: RGC) (“Regencell”) today announced its interim results from its second efficacy trial. Regencell conducted
Sector Rotation And 9 Stocks To Watch During A Recession
06:56pm, Wednesday, 18'th May 2022
Is the United States heading toward a recession? This has been the looming question on the minds of Americans since inflation topped at 8.5% in March, matched with other indicators such as rising int
HONG KONG--(BUSINESS WIRE)---- $RGC #ADHD--Regencell Bioscience Holdings Limited (NASDAQ: RGC): Results of EARTH efficacy trial EARTH Efficacy Trials Period of trial 30 January 2022 – 31 March 20
Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO
08:56am, Monday, 16'th May 2022
HONG KONG--(BUSINESS WIRE)---- $RGC #ADHD--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focusing on the research, devel
Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO
07:00am, Monday, 16'th May 2022
HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focusing on the research, development and comm
LOS ANGELES, CA / ACCESSWIRE / March 1, 2022 / SNN Network, The Official Small-, Micro- and Nano-Cap News Source™, today published a new Video Interview with the team from Regencell Bioscience Holdi
リジェンセル・バイオサイエンスの液体処方治験薬RGC-COV19TMがEARTH有効性試験に組み入れた患者で有効性を示し、6日間の治療期間中に軽度から中等度のCOVID-19症状を解消
08:40am, Tuesday, 22'nd Feb 2022
香港--(BUSINESS WIRE)--（ビジネスワイヤ） -- リジェンセル・バイオサイエンス・ホールディングス・リミテッド（NASDAQ: RGC）（「リジェンセル」または�
HONGKONG--(BUSINESS WIRE)-- A Regencell Bioscience RGC-COV19TM elnevezésű új, folyékony vizsgálati készítménye az azt értékelő EARTH hatásossági vizsgálat során hatásosnak mutatkozott
HONG KONG--(BUSINESS WIRE)-- Płynna formuła RGC-COV19TM Regencell Bioscience w fazie badań eksperymentalnych wykazuje skuteczność w eliminowaniu łagodnych i umiarkowanych objawów COVID-19 u pac
脑再生科技有限公司的EARTH有效性试验显示，其试验中RGC-COV19™液体方剂可以在6天疗程中有效清除入组患者的COVID-19轻至中度症状
11:32pm, Sunday, 20'th Feb 2022
香港--(BUSINESS WIRE)--(美国商业资讯)--脑再生科技有限公司(NASDAQ: RGC)（“脑 再生”或“ 公司”）今天发布了由脑再生科技(亞洲)有限公司 (“脑再生(亞洲)
腦再生科技有限公司 的EARTH有效性試驗顯示，其試驗中RGC-COV19™ 液體方劑可以在6天療程中有效清除入組患者的COVID-19輕至中度症狀
11:32pm, Sunday, 20'th Feb 2022
香港--(BUSINESS WIRE)--(美國商業資訊)--腦再生科技有限公司 (NASDAQ: RGC)（ “ 腦再生 ” 或 “ 公司”）今天發表了由腦再生科技(亞洲)有限公司 (“腦再生(�
HONGKONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ: RGC) ('Regencell' of het 'Bedrijf') heeft vandaag de resultaten bekendgemaakt van een analyse van in totaal 37 personen die de
HONG KONG--(BUSINESS WIRE)-- La formule liquide expérimentale RGC-COV19TM de Regencell Bioscience a démontré son efficacité, chez ses patients recrutés, dans l'élimination des symptômes légers
